Estrella Immunopharma, Inc. ESLA
company developing T-cell therapies to address treatment challenges for patients with cancers and autoimmune diseases. Our strategy is
to harness the evolutionary power of the human immune system to provide patients with potentially safer, more efficacious T-cell therapies
compared to traditional CAR-T therapies. Leveraging cutting-edge cellular engineering technologies, we aim to overcome the limitations
of current CAR-T therapies, such as high toxicity and prohibitive costs, so that T-cell therapy treatments can be accessible to a larger
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| R&D | $10.2M | $4.1M | $10.5M | — | — | — |
| SG&A | $2.8M | $3.2M | $663.2K | — | — | — |
| Total operating expenses | $13.1M | $7.3M | $11.1M | — | — | — |
| Operating income | -$13.1M | -$7.3M | -$11.1M | -$1.6M | -$249.1K | — |
| Pre-tax income | -$13.1M | -$7.3M | -$11.1M | -$915.5K | -$247.7K | — |
| Income tax | $838 | $1.6K | — | $80.6K | $0 | — |
| Net income | -$13.1M | -$7.3M | -$11.1M | -$996.1K | -$247.7K | — |
| EPS, basic | -0.35 | -0.27 | -36.35 | — | — | — |
| EPS, diluted | -0.35 | -0.27 | -36.35 | — | — | — |
| Shares, diluted (wtd. avg.) | 36.8M | 27.1M | 305,748 | — | 1.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $1.4M | $916.9K | $2.5M | $4.1M | $478.9K | — |
| Total current assets | $1.7M | $1.6M | $2.8M | $52.4K | $616.0K | — |
| Total assets | $3.2M | $3.1M | $3.0M | $9.7M | $45.8M | — |
| Accounts payable | — | — | — | $329.2K | $3.0K | — |
| Total current liabilities | $13.5M | $3.0M | $9.8M | $1.1M | $73.2K | — |
| Total liabilities | $13.5M | $3.0M | $9.8M | $2.7M | $1.6M | — |
| Retained earnings | -$37.0M | -$23.9M | -$12.2M | -$2.3M | -$1.0M | — |
| Total equity | -$10.4M | $4.3M | -$11.7M | -$1.0M | -$1.0M | $0 |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$1.8M | -$16.1M | -$1.3M | -$1.0M | -$316.2K | — |
| Stock-based compensation | $619.0K | $1.2M | $409.6K | — | — | — |
| Investing cash flow | — | $5.0M | -$273.1K | $36.2M | -$45.2M | — |
| Financing cash flow | $2.3M | $12.8M | — | -$35.6M | $46.0M | — |
| Buybacks | $29.5K | $354.4K | $1.0M | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-050433.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Net income | — | -$247.7K | -$996.1K | -$11.1M | -$7.3M | -$13.1M |
Recent filings and events
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Delisting notice Item 3.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Delisting notice Item 3.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |